AXL and neoplasm: Foretinib is an oral multi-kinase inhibitor targeting MET, ROS, RON, AXL, TIE-2, and VEGFR (Choueiri et al., 2013), which has demonstrated good anti-tumor activity and tolerability in a phase I/II single-arm study (Yau et al., 2017).